Pulmonx Corporation (LUNG) Reports 75.8% Collateral Ventilation Conversion
Pulmonx (LUNG) reported 75.8% of patients converted from CV+ to CV− after AeriSeal treatment in the CONVERT Trial. 88.9% of evaluable patients achieved significant target-lobe volume reduction with Zephyr Valves. AeriSeal is under pivotal evaluation, with CONVERT II results needed for U.S. PMA application.

